News Sentiment

ARTL sentiment intelligence

Artelo Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.15 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+6.5% over one week, -8.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 6.5% Price confirming higher
Trend fit Trend inactive -8.7% over four weeks
Fair value -93.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 36
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 9
Quiver Quantitative 4
TradingView 3
Investing.com 3
The Manila Times 3
GlobeNewswire 3
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 20
Regulatory and legal 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
The Manila Times Direct company coverage

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

Artelo Biosciences announced multi-omics analysis results at the ICRS 2026 Annual Symposium, highlighting linoleic acid as a critical lipid modulated by their lead FABP5 inhibitor, ART26.12. This finding suggests a common mechanistic link for FABP5 inhibition across various disea

Tone
Positive 71/100
Event
Earnings
Published
30 Jun 2026 21:09
Source
The Manila Times
Stock Titan Direct company coverage

Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models

Artelo Biosciences announced new multi-omics data for its selective FABP5 inhibitor, ART26.12, showing consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways across various disease models. This suggests a potential mechanistic link

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 12:39
Source
Stock Titan
Quiver Quantitative Direct company coverage

Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research

Artelo Biosciences announced positive Phase 1 clinical trial results for ART26.12, its selective FABP5 inhibitor, showing a favorable safety profile and predictable pharmacokinetics. The study highlighted ART26.12's potential as a non-opioid analgesic for chemotherapy-induced per

Tone
Positive 74/100
Event
Earnings
Published
29 Jun 2026 21:09
Source
Quiver Quantitative
Stock Titan Direct company coverage

Artelo’s first-in-human FABP5 inhibitor shows tolerability, biomarker signals

Artelo Biosciences reported positive Phase 1 clinical data for its selective FABP5 inhibitor, ART26.12, at ICRS 2026. The study found ART26.12 to be well-tolerated with predictable pharmacokinetics, and AI-driven analysis identified treatment-related changes in various biological

Tone
Positive 80/100
Event
Market update
Published
29 Jun 2026 13:10
Source
Stock Titan
Market source Direct company coverage

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

Artelo Biosciences announced the presentation of clinical and biomarker data for ART26.12, its selective FABP5 inhibitor, at the ICRS 2026 Annual Symposium. The presentations highlighted favorable safety and pharmacokinetic profiles from a Phase 1 study and identified potential b

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 13:10
Source
Market source
TradingView Direct company coverage

Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL)

This article provides details on Artelo Biosciences, Inc. (NASDAQ: ARTL), including its current stock price, historical performance, market capitalization, and upcoming earnings report. As of June 26, 2026, ARTL's stock price is $1.12, having decreased significantly year-over-yea

Tone
Negative 38/100
Event
Earnings
Published
26 Jun 2026 19:40
Source
TradingView
Stock Titan Direct company coverage

Artelo Biosciences (ARTL) asks shareholders to approve >20% issuance to Square Gate

Artelo Biosciences is seeking shareholder approval for Proposal 3, which would allow the company to issue more than 20% of its common stock under an existing Equity Purchase Agreement (EPA) with Square Gate Capital Master Fund, LLC – Series 5. This approval is necessary to comply

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 20:10
Source
Stock Titan
TradingKey Direct company coverage

Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides an analysis of Artelo Biosciences Inc (ARTL), detailing its stock performance and market capitalization. It highlights that critical revenue breakdown data, including information by business segment and region, has not yet been disclosed by the company. The

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 09:15
Source
TradingKey